Background illustration for clinical trials search

Weight Loss Clinical Trials

Find clinical trials for weight loss. Search for weight loss clinical trials in different cities and states across the United States.

Filter
Active & Responsive

Optimizing an Online Behavioral Weight Loss Intervention and Novel Culturally Tailored Components for Sexual Minority Women

for
Obesity
Location: Providence RI
Sponsor: The Miriam Hospital

Sex: Female

Age: 18 - 70

Code: NCT05775497

Recruiting
Active & Responsive

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

for
Obesity
Location: New York NY, Philadelphia PA
Sponsor: University of Pittsburgh

Sex: All

Age: 25 - 59

Code: NCT05748158

Recruiting
Active & Responsive

Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity

for
Obesity
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 18 - 65

Code: NCT06736028

Recruiting
Active & Responsive

Weight Loss Through Mayo Clinic Diet

for
Obesity
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18 - 64

Code: NCT06862375

Recruiting
Active & Responsive

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

for
Obesity
Location: New York NY
Sponsor: Columbia University

Sex: All

Age: 18 - 65

Code: NCT05919797

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

for
Overweight , Obesity, Adults
Location: New York NY, Wilmington NC, Doral FL, Orlando FL,
Sponsor: Alveus Therapeutics, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07837973

Phase 2, Recruiting
Active & Responsive

SMARTer Weight Loss Management

for
Obesity
Location: Tallahassee FL
Sponsor: Florida State University

Sex: All

Age: 18+

Code: NCT05861973

Recruiting
Active & Responsive

Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

for
Volume Loss (Soft Tissue Ptosis or Atrophy )
Location: Pasadena CA
Sponsor: Kalpna Kay Durairaj, MD, FACS

Sex: All

Age: 21 - 65

Code: NCT07419854

Recruiting
Active & ResponsiveNew

Mechanisms of Weight Loss: Tirzepatide vs Semaglutide

for
Obesity (Disorder)
Location: Hamilton
Sponsor: McMaster University

Sex: All

Age: 18 - 60

Code: NCT07900074

Phase 4, Recruiting
Active & ResponsiveNew

A Trial to Examine the Effects of a Weight Loss Program Emphasizing Protein, Dietary Fiber, and Exercise (30-30-30 Plan)

for
Overweight , Obesity
Location: Bloomington IN, Chicago IL, Addison IL
Sponsor: Midwest Center for Metabolic and Cardiovascular Research

Sex: All

Age: 18 - 69

Code: NCT07789769

Recruiting
Active & Responsive

Comparision of Aerobic Exercise to Aerobic Plus Yoga Exercise for Weight Loss in Adults With Overweight or Obesity.

for
Obesity and Overweight
Location: Kansas City KS
Sponsor: University of Kansas Medical Center

Sex: All

Age: 18+

Code: NCT06636773

Recruiting
Active & Responsive

Plant-Based Online Weight Loss Through Education and Resources Program and Study

for
Type 2 Diabetes, Overweight and Obese Adults
Location: Washington D.C. DC
Sponsor: Physicians Committee for Responsible Medicine

Sex: All

Age: 18+

Code: NCT07095543

Recruiting
Active & Responsive

Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain

for
Overweight or Obesity
Location: Springfield OR
Sponsor: ORI Community and Evaluation Services

Sex: All

Age: 18 - 70

Code: NCT07708064

Recruiting
Active & Responsive

Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms

for
Premenstrual Syndrome, Menstrual Cycle,
Location: Colorado Springs CO
Sponsor: University of Colorado, Colorado Springs

Sex: Female

Age: 18 - 40

Code: NCT07084714

Recruiting
Active & Responsive

Delivering tAN to Reduce HMB: The LUNA Study

for
Heavy Menstrual Bleeding
Location: Boston MA
Sponsor: Spark Biomedical, Inc.

Sex: Female

Age: 14 - 45

Code: NCT07326722

Recruiting

The Effect of Time Restricted Feeding on Fat Mass in Overweight Women

for
Weight Loss
Location: London
Sponsor: University of Western Ontario, Canada

Sex: Female

Age: 18 - 30

Code: NCT02629900

Recruiting

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

for
Obesity and Overweight, Diabetes Mellitus, Weight Loss,
Location: Chapel Hill NC
Sponsor: University of North Carolina, Chapel Hill

Sex: All

Age: 18 - 70+

Code: NCT06724406

Recruiting

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

for
Obesity, Adolescent Obesity, Body-Weight Trajectory,
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 12 - 24

Code: NCT06575738

Phase 1, Recruiting

The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction

for
Weight Loss, Obesity
Location: London
Sponsor: University of Western Ontario, Canada

Sex: Female

Age: 18 - 25

Code: NCT02630238

Recruiting

Food Cravings Strategies During Dietary Weight Loss

for
Obesity, Food Cravings, Weight Loss
Location: Urbana IL
Sponsor: University of Illinois at Urbana-Champaign

Sex: All

Age: 18 - 70+

Code: NCT06280339

Recruiting

What weight loss treatments are being studied

GLP-1 and combination medicines. The medicines that reshaped the field mimic a gut hormone called GLP-1 that signals fullness and slows digestion. Semaglutide (Wegovy) was approved for weight management in June 2021 and produced about 15 percent weight loss in its main trial; tirzepatide (Zepbound), which acts on GLP-1 and a second hormone, GIP, was approved in November 2023 and produced up to about 21 percent. Trials now test medicines that add a third hormone signal or pair a GLP-1 with amylin, another appetite hormone, aiming for larger and more durable weight loss; the CagriSema combination, for example, is under FDA review after Phase 3 trials, and its confirmatory studies are still enrolling.

Pills. For years every effective option was an injection. In December 2025 the FDA approved a semaglutide tablet (Wegovy pill), and on April 1, 2026 it approved orforglipron (Foundayo), the first GLP-1 pill that can be taken at any time without food or water restrictions, after trials in which people lost about 11 to 12 percent of body weight over 72 weeks. Current orforglipron trials test the pill in groups the approval studies did not cover, including adolescents and people who have already lost weight on an injection and want to maintain it.

Weight loss surgery. Bariatric surgery remains the most effective and longest lasting treatment for severe obesity, with roughly a quarter of a million operations performed in the US each year, most of them sleeve gastrectomy or gastric bypass. Trials study how surgery changes metabolism, how to prevent weight regain afterward, and how surgery compares with or combines with the new medicines.

Devices and endoscopic procedures. Between medicine and surgery sit procedures done through the mouth with no incision: endoscopic sleeve gastroplasty, which stitches the stomach smaller from the inside and was authorized by the FDA in 2022; intragastric balloons, which sit in the stomach for six months; and revision procedures for people who regained weight after bypass. Trials compare newer devices against established ones and measure how long results hold.

GLP-1 medication trials

Weight loss surgery and device trials

Who can participate in weight loss treatment trials

Do participants get paid?

How to enroll in a weight loss clinical trial